<DOC>
	<DOCNO>NCT01796795</DOCNO>
	<brief_summary>This phase II study evaluate efficacy SR-T100 gel complete clearance target wart different concentration ( 1.0 % 2.3 % SM Solanum undatum plant extract ) patient CW .</brief_summary>
	<brief_title>Efficacy Safety SR-T100 Gel Common Warts ( CW ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Warts</mesh_term>
	<criteria>1 . Age ≥ 17 year old . 2 . The diagnosis CW base visual inspection experience dermatologist . 3 . Patient select ≤ 5 CW lesion ; target lesion ( ) need ≤ 15 mm diameter . For patient 1 select lesion , size target lesion need measure 2 15 mm diameter . 4 . Patient agree apply study medication target CW lesion ( ) occlusive dress least 20 hour per day . 5 . Patient legally acceptable representative patient 20 year age , willing able provide write informed consent . 6 . Patient agree use wartremoving product/modality ( prescription overthecounter ) study product course study ; willing refrain use cosmetic topical product treatment area duration study . 7 . Any nontarget CW receive wartremoving procedure include cryotherapy surgical therapy least 5 cm apart target lesion . 8 . Patient free systemic dermatologic disorder , , opinion investigator , interfere study result increase risk patient . 9 . Patient judge good health base upon result physical examination ( PEs ) , medical history , safety laboratory test . 10 . Patient good general health condition ( performance status ≤ 2 Eastern Cooperative Oncology Group ( ECOG ) ) . 11 . Patient agrees photograph CW target lesion ( ) use data part study package . 12 . Female patient childbearing potential negative urine serum pregnancy test Screening day , willing use effective contraception study . 1 . The treatment area locate follow area : eye area ( include eyelid ) , lip , mouth cavity , nasal cavity , inner ear , sole foot , underneath nail , anogenital area . 2 . Patient participate clinical study within 30 day prior Randomization visit , currently participate another clinical study . 3 . Patient use wartremoving product/modality treatment area within 30 day prior Randomization visit receive cryotherapy treatment area within 60 day prior Randomization visit . 4 . Patient immunecompromised condition , require require systemic intake immunosuppressive immunomodulatory medication ( oral parental corticosteroid include ) within 30 day prior Randomization visit course study . Routine use inhale intranasal corticosteroid study allow . 5 . Patient clinically significant unstable medical condition ( psychologically physically ) follow list situation : 1 . Clinically significant peripheral vascular disease base medical history . 2 . Current uncontrolled infection , current skin infection and/or skin disorder treatment area CW and/or area surround wart may confound affect study assessment procedure study endpoint . 3 . Chronic acute medical condition , opinion investigator , may interfere study result place subject undue risk ( include human immunodeficiency virus , systemic lupus erythematosis , active viral hepatitis , etc. ) . 6 . Patient pregnant , plan become pregnant , breastfeed . 7 . Patient history allergy sensitivity Solanum undatum plant extract , SM , SRT100 gel excipients include carbomer , propylene glycol , triethanolamine .</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>common wart</keyword>
	<keyword>verruca vulgaris</keyword>
</DOC>